biote (BTMD) Set to Announce Quarterly Earnings on Tuesday

biote (NASDAQ:BTMD) will be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of $0.05 per share for the quarter. biote has set its FY 2024 guidance at EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

biote (NASDAQ:BTMD) last posted its quarterly earnings data on Tuesday, March 12th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.08 by $0.06. biote had a negative return on equity of 45.10% and a net margin of 1.79%. The firm had revenue of $45.70 million for the quarter, compared to the consensus estimate of $45.50 million. On average, analysts expect biote to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

biote Trading Up 4.0 %

Shares of NASDAQ:BTMD opened at $6.01 on Monday. The stock has a 50 day moving average of $5.86 and a 200 day moving average of $5.18. biote has a 12-month low of $3.65 and a 12-month high of $8.22.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BTMD. Truist Financial reduced their price objective on shares of biote from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, January 18th. Jefferies Financial Group started coverage on biote in a research report on Thursday, February 1st. They issued a “buy” rating and a $6.55 price objective on the stock. Roth Mkm reiterated a “buy” rating and set a $9.00 target price (up previously from $8.00) on shares of biote in a research report on Wednesday, March 13th. Finally, B. Riley initiated coverage on biote in a report on Tuesday, February 20th. They issued a “buy” rating and a $9.00 price target on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat, biote has an average rating of “Buy” and an average price target of $8.11.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.